Article

B&L shareholders OK Warburg Pincus merger

Bausch & Lomb (B&L) shareholders have approved the proposed merger of the company with affiliates of Warburg Pincus LLC, according to the company.

Rochester, NY-Bausch & Lomb (B&L) shareholders have approved the proposed merger of the company with affiliates of Warburg Pincus LLC, according to the company.

"We look forward to completing the transaction promptly," said Ronald L. Zarrella, B&L chairman and chief executive officer.

The transaction is expected to close early in the fourth quarter. Each outstanding share of B&L common and Class B stock will be canceled and converted into the right to receive $65 in cash, without interest and minus any applicable withholding taxes.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.